Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO Subscriptions PDA Services My JCO Customer Service

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bonomi, P.
Right arrow Articles by Johnson, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bonomi, P.
Right arrow Articles by Johnson, D.
Journal of Clinical Oncology, Vol 18, Issue 3 (February), 2000: 623
© 2000 American Society for Clinical Oncology

Comparison of Survival and Quality of Life in Advanced Non–Small-Cell Lung Cancer Patients Treated With Two Dose Levels of Paclitaxel Combined With Cisplatin Versus Etoposide With Cisplatin: Results of an Eastern Cooperative Oncology Group Trial

By Philip Bonomi, KyungMann Kim, Diane Fairclough, David Cella, John Kugler, Eric Rowinsky, Michael Jiroutek, David Johnson

From the Rush-Presbyterian St. Luke’s Medical Center, Chicago; Illinois Oncology Research Association, Peoria; and Evanston Northwestern Health Care, Northwestern University, Evanston, IL; University of Wisconsin Comprehensive Cancer Center, Madison, WI; American Medical Center Cancer Research Center, Denver, CO; Cancer Therapy and Research Center, San Antonio, TX; Dana-Farber Cancer Center, Boston, MA; and Vanderbilt University, Nashville, TN.

Address reprint requests to Philip Bonomi, MD, Rush Medical College, 1725 West Harrison St, Ste 821, Chicago, IL; email bonomi.phil{at}jimmy.harvard.edu

PURPOSE: Treatment with cisplatin-based chemotherapy provides a modest survival advantage over supportive care alone in advanced non–small-cell lung cancer (NSCLC). To determine whether a new agent, paclitaxel, would further improve survival in NSCLC, the Eastern Cooperative Oncology Group conducted a randomized trial comparing paclitaxel plus cisplatin to a standard chemotherapy regimen consisting of cisplatin and etoposide.

PATIENTS AND METHODS: The study was carried out by a multi-institutional cooperative group in chemotherapy-naive stage IIIB to IV NSCLC patients randomized to receive paclitaxel plus cisplatin or etoposide plus cisplatin. Paclitaxel was administered at two different dose levels (135 mg/m2 and 250 mg/m2), and etoposide was given at a dose of 100 mg/m2 daily on days 1 to 3. Each regimen was repeated every 21 days and each included cisplatin (75 mg/m2).

RESULTS: The characteristics of the 599 patients were well-balanced across the three treatment groups. Superior survival was observed with the combined paclitaxel regimens (median survival time, 9.9 months; 1-year survival rate, 38.9%) compared with etoposide plus cisplatin (median survival time, 7.6 months; 1-year survival rate, 31.8%; P = .048). Comparing survival for the two dose levels of paclitaxel revealed no significant difference. The median survival duration for the stage IIIB subgroup was 7.9 months for etoposide plus cisplatin patients versus 13.1 months for all paclitaxel patients (P = .152). For the stage IV subgroup, the median survival time for etoposide plus cisplatin was 7.6 months compared with 8.9 months for paclitaxel (P = .246).

With the exceptions of increased granulocytopenia on the low-dose paclitaxel regimen and increased myalgias, neurotoxicity, and, possibly, increased treatment-related cardiac events with high-dose paclitaxel, toxicity was similar across all three arms. Quality of life (QOL) declined significantly over the 6 months. However, QOL scores were not significantly different among the regimens.

CONCLUSION: As a result of these observations, paclitaxel (135 mg/m2) combined with cisplatin has replaced etoposide plus cisplatin as the reference regimen in our recently completed phase III trial.




This article has been cited by other articles:


Home page
 JCOHome page
M. J. Edelman, D. Watson, X. Wang, C. Morrison, R. A. Kratzke, S. Jewell, L. Hodgson, A. M. Mauer, A. Gajra, G. A. Masters, et al.
Eicosanoid Modulation in Advanced Lung Cancer: Cyclooxygenase-2 Expression Is a Positive Predictive Factor for Celecoxib + Chemotherapy--Cancer and Leukemia Group B Trial 30203
J. Clin. Oncol., February 20, 2008; 26(6): 848 - 855.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. S. Ramalingam, S. E. Dahlberg, C. J. Langer, R. Gray, C. P. Belani, J. R. Brahmer, A. B. Sandler, J. H. Schiller, and D. H. Johnson
Outcomes for Elderly, Advanced-Stage Non Small-Cell Lung Cancer Patients Treated With Bevacizumab in Combination With Carboplatin and Paclitaxel: Analysis of Eastern Cooperative Oncology Group Trial 4599
J. Clin. Oncol., January 1, 2008; 26(1): 60 - 65.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
D. -W. Kim, S. -Y. Kim, H. -K. Kim, S. -W. Kim, S. W. Shin, J. S. Kim, K. Park, M. Y. Lee, and D. S. Heo
Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer
Ann. Onc., December 1, 2007; 18(12): 2009 - 2014.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
M. A. Socinski, R. Crowell, T. E. Hensing, C. J. Langer, R. Lilenbaum, A. B. Sandler, and D. Morris
Treatment of Non-small Cell Lung Cancer, Stage IV: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition)
Chest, September 1, 2007; 132(3_suppl): 277S - 289S.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
G. R. Simon and A. Turrisi
Management of Small Cell Lung Cancer: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition)
Chest, September 1, 2007; 132(3_suppl): 324S - 339S.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
Y. Fujiwara, I. Sekine, K. Tsuta, Y. Ohe, H. Kunitoh, N. Yamamoto, H. Nokihara, K. Yamada, and T. Tamura
Effect of Platinum Combined with Irinotecan or Paclitaxel against Large Cell Neuroendocrine Carcinoma of the Lung
Jpn. J. Clin. Oncol., July 24, 2007; (2007) hym053v1.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
G. Weiss, R Rosell, F Fossella, M Perry, R Stahel, F Barata, B Nguyen, S Paul, P McAndrews, N Hanna, et al.
The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer
Ann. Onc., March 1, 2007; 18(3): 453 - 460.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
P Comella, G Filippelli, G De Cataldis, B Massidda, G Frasci, L Maiorino, C Putzu, S Mancarella, S Palmeri, R Cioffi, et al.
Efficacy of the combination of cisplatin with either gemcitabine and vinorelbine or gemcitabine and paclitaxel in the treatment of locally advanced or metastatic non-small-cell lung cancer: a phase III randomised trial of the Southern Italy Cooperative Oncology Group (SICOG 0101)
Ann. Onc., February 1, 2007; 18(2): 324 - 330.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. D. Colevas
Chemotherapy Options for Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
J. Clin. Oncol., June 10, 2006; 24(17): 2644 - 2652.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
C. A. Dooms, Y. N. Lievens, and J. F. Vansteenkiste
Cost-utility analysis of chemotherapy in symptomatic advanced nonsmall cell lung cancer
Eur. Respir. J., May 1, 2006; 27(5): 895 - 901.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. J. Fallowfield, J. M. Bliss, L. S. Porter, M. H. Price, C. F. Snowdon, S. E. Jones, R. C. Coombes, and E. Hall
Quality of Life in the Intergroup Exemestane Study: A Randomized Trial of Exemestane Versus Continued Tamoxifen After 2 to 3 Years of Tamoxifen in Postmenopausal Women With Primary Breast Cancer
J. Clin. Oncol., February 20, 2006; 24(6): 910 - 917.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. J. Edelman, R. Smith, P. Hausner, L. A. Doyle, K. Kalra, J. Kendall, M. Bedor, and S. Bisaccia
Phase II Trial of the Novel Retinoid, Bexarotene, and Gemcitabine Plus Carboplatin in Advanced Non-Small-Cell Lung Cancer
J. Clin. Oncol., August 20, 2005; 23(24): 5774 - 5778.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
B. Besse, J. C. Soria, and T. Le Chevalier
Front-line doublets in advanced non-small cell lung cancer: The golden age for second line chemotherapy
Ann. Onc., July 1, 2005; 16(7): 997 - 998.
[Full Text] [PDF]

Home page
 Ann OncolHome page
C. P. Belani, J. S. Lee, M. A. Socinski, F. Robert, D. Waterhouse, K. Rowland, R. Ansari, R. Lilenbaum, and R. B. Natale
Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer
Ann. Onc., July 1, 2005; 16(7): 1069 - 1075.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
T. Winton, R. Livingston, D. Johnson, J. Rigas, M. Johnston, C. Butts, Y. Cormier, G. Goss, R. Inculet, E. Vallieres, et al.
Vinorelbine plus Cisplatin vs. Observation in Resected Non-Small-Cell Lung Cancer
N. Engl. J. Med., June 23, 2005; 352(25): 2589 - 2597.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. D. Bradley, R. Paulus, M. V. Graham, D. S. Ettinger, D. W. Johnstone, M. V. Pilepich, M. Machtay, R. Komaki, J. Atkins, and W. J. Curran
Phase II Trial of Postoperative Adjuvant Paclitaxel/Carboplatin and Thoracic Radiotherapy in Resected Stage II and IIIA Non-Small-Cell Lung Cancer: Promising Long-Term Results of the Radiation Therapy Oncology Group--RTOG 9705
J. Clin. Oncol., May 20, 2005; 23(15): 3480 - 3487.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. H. Lee, J.-Y. Han, H. G. Lee, J. J. Lee, E. K. Lee, H. Y. Kim, H. K. Kim, E. K. Hong, and J. S. Lee
Gefitinib as a First-Line Therapy of Advanced or Metastatic Adenocarcinoma of the Lung in Never-Smokers
Clin. Cancer Res., April 15, 2005; 11(8): 3032 - 3037.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
F. Waechter, J. Passweg, M. Tamm, M. Brutsche, R. Herrmann, and M. Pless
Significant Progress in Palliative Treatment of Non-small Cell Lung Cancer in the Past Decade
Chest, March 1, 2005; 127(3): 738 - 747.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
I. S. Choi, D.-Y. Oh, J. H. Kwon, S.-I. Kim, S. R. Park, J.-Y. Bak, J. H. Kim, D.-W. Kim, Y. T. Kim, T.-Y. Kim, et al.
Paclitaxel/Platinum-based Perioperative Chemotherapy and Surgery in Stage IIIA Non-small Cell Lung Cancer
Jpn. J. Clin. Oncol., January 1, 2005; 35(1): 6 - 12.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. Hoang, R. Xu, J. H. Schiller, P. Bonomi, and D. H. Johnson
Clinical Model to Predict Survival in Chemonaive Patients With Advanced Non-Small-Cell Lung Cancer Treated With Third-Generation Chemotherapy Regimens Based on Eastern Cooperative Oncology Group Data
J. Clin. Oncol., January 1, 2005; 23(1): 175 - 183.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
D. J. Stewart
Update on the Role of Topotecan in the Treatment of Non-Small Cell Lung Cancer
Oncologist, December 1, 2004; 9(suppl_6): 43 - 52.
[Abstract] [Full Text] [PDF]

Home page
 J Natl Cancer Inst MonogrHome page
C. C. Earle
Outcomes Research in Lung Cancer
J Natl Cancer Inst Monographs, October 1, 2004; 2004(33): 56 - 77.
[Abstract] [Full Text] [PDF]

Home page
 J Natl Cancer Inst MonogrHome page
C. C. Gotay
Assessing Cancer-Related Quality of Life Across a Spectrum of Applications
J Natl Cancer Inst Monographs, October 1, 2004; 2004(33): 126 - 133.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
A. Sedrakyan, J. van Der Meulen, K. O'Byrne, J. Prendiville, J. Hill, and T. Treasure
Postoperative chemotherapy for non-small cell lung cancer: A systematic review and meta-analysis
J. Thorac. Cardiovasc. Surg., September 1, 2004; 128(3): 414 - 419.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. H. Moore, J. A. Blessing, R. P. McQuellon, H. T. Thaler, D. Cella, J. Benda, D. S. Miller, G. Olt, S. King, J. F. Boggess, et al.
Phase III Study of Cisplatin With or Without Paclitaxel in Stage IVB, Recurrent, or Persistent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study
J. Clin. Oncol., August 1, 2004; 22(15): 3113 - 3119.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. J. Edelman, J. I. Clark, K. Chansky, K. Albain, N. Bhoopalam, G. R. Weiss, J. K. Giguere, K. Kelly, J. Crowley, and D. R. Gandara
Randomized Phase II Trial of Sequential Chemotherapy in Advanced Non-Small Cell Lung Cancer (SWOG 9806): Carboplatin/Gemcitabine followed by Paclitaxel or Cisplatin/Vinorelbine followed by Docetaxel
Clin. Cancer Res., August 1, 2004; 10(15): 5022 - 5026.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
G. P. Stathopoulos, M. Veslemes, N. Georgatou, D. Antoniou, P. Giamboudakis, K. Katis, D. Tsavdaridis, S. K. Rigatos, I. Dimitroulis, S. Bastani, et al.
Front-line paclitaxel-vinorelbine versus paclitaxel-carboplatin in patients with advanced non-small-cell lung cancer: a randomized phase III trial
Ann. Onc., July 1, 2004; 15(7): 1048 - 1055.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
P. L. R. Mitchell, R. Basser, M. Chipman, A. Grigg, R. Mansfield, J. Cebon, I. D. Davis, F. Appia, and M. Green
A phase II study of escalated-dose docetaxel with granulocyte colony-stimulating factor support in patients with advanced breast cancer
Ann. Onc., April 1, 2004; 15(4): 585 - 589.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
C. M. Rocha Lima, N. A. Rizvi, C. Zhang, J. E. Herndon 2nd, J. Crawford, R. Govindan, G. W. King, and M. R. Green
Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC
Ann. Onc., March 1, 2004; 15(3): 410 - 418.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
A. Spira and D. S. Ettinger
Multidisciplinary Management of Lung Cancer
N. Engl. J. Med., January 22, 2004; 350(4): 379 - 392.
[Full Text] [PDF]

Home page
 JCOHome page
D. G. Pfister, D. H. Johnson, C. G. Azzoli, W. Sause, T. J. Smith, S. Baker Jr, J. Olak, D. Stover, J. R. Strawn, A. T. Turrisi, et al.
American Society of Clinical Oncology Treatment of Unresectable Non-Small-Cell Lung Cancer Guideline: Update 2003
J. Clin. Oncol., January 15, 2004; 22(2): 330 - 353.
[Full Text] [PDF]

Home page
 JCOHome page
K. Kubota, K. Watanabe, H. Kunitoh, K. Noda, Y. Ichinose, N. Katakami, T. Sugiura, M. Kawahara, A. Yokoyama, S. Yokota, et al.
Phase III Randomized Trial of Docetaxel Plus Cisplatin Versus Vindesine Plus Cisplatin in Patients With Stage IV Non-Small-Cell Lung Cancer: The Japanese Taxotere Lung Cancer Study Group
J. Clin. Oncol., January 15, 2004; 22(2): 254 - 261.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. F. Smit, J. P.A.M. van Meerbeeck, P. Lianes, C. Debruyne, C. Legrand, F. Schramel, H. Smit, R. Gaafar, B. Biesma, C. Manegold, et al.
Three-Arm Randomized Study of Two Cisplatin-Based Regimens and Paclitaxel Plus Gemcitabine in Advanced Non-Small-Cell Lung Cancer: A Phase III Trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975
J. Clin. Oncol., November 1, 2003; 21(21): 3909 - 3917.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
F. Fossella, J. R. Pereira, J. von Pawel, A. Pluzanska, V. Gorbounova, E. Kaukel, K. V. Mattson, R. Ramlau, A. Szczesna, P. Fidias, et al.
Randomized, Multinational, Phase III Study of Docetaxel Plus Platinum Combinations Versus Vinorelbine Plus Cisplatin for Advanced Non-Small-Cell Lung Cancer: The TAX 326 Study Group
J. Clin. Oncol., August 15, 2003; 21(16): 3016 - 3024.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. H. Takimoto and E. K. Rowinsky
Dose-Intense Paclitaxel: Deja Vu All Over Again?
J. Clin. Oncol., August 1, 2003; 21(15): 2810 - 2814.
[Full Text] [PDF]

Home page
 JCOHome page
G. A. Omura, M. F. Brady, K. Y. Look, H. E. Averette, J. E. Delmore, H. J. Long, S. Wadler, G. Spiegel, and S. G. Arbuck
Phase III Trial of Paclitaxel at Two Dose Levels, the Higher Dose Accompanied by Filgrastim at Two Dose Levels in Platinum-Pretreated Epithelial Ovarian Cancer: An Intergroup Study
J. Clin. Oncol., August 1, 2003; 21(15): 2843 - 2848.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Bottomley, F. Efficace, R. Thomas, V. Vanvoorden, and S. H. Ahmedzai
Health-Related Quality of Life in Non-Small-Cell Lung Cancer: Methodologic Issues in Randomized Controlled Trials
J. Clin. Oncol., August 1, 2003; 21(15): 2982 - 2992.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
B.T. Hennessy, E.O. Hanrahan, and O.S. Breathnach
Chemotherapy Options for the Elderly Patient with Advanced Non-Small Cell Lung Cancer
Oncologist, June 1, 2003; 8(3): 270 - 277.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. T. Eton, D. L. Fairclough, D. Cella, S. E. Yount, P. Bonomi, and D. H. Johnson
Early Change in Patient-Reported Health During Lung Cancer Chemotherapy Predicts Clinical Outcomes Beyond Those Predicted by Baseline Report: Results From Eastern Cooperative Oncology Group Study 5592
J. Clin. Oncol., April 15, 2003; 21(8): 1536 - 1543.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
M Cullen
Lung cancer * 4: Chemotherapy for non-small cell lung cancer: the end of the beginning
Thorax, April 1, 2003; 58(4): 352 - 356.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
C. Gridelli, F. Perrone, C. Gallo, S. Cigolari, A. Rossi, F. Piantedosi, S. Barbera, F. Ferrau, E. Piazza, F. Rosetti, et al.
Chemotherapy for Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) Phase III Randomized Trial
J Natl Cancer Inst, March 5, 2003; 95(5): 362 - 372.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. J. Millward, M. J. Boyer, M. Lehnert, S. Clarke, D. Rischin, B.-C. Goh, J. Wong, E. McNeil, and J. F. Bishop
Docetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: a phase II study in Caucasian and Asian patients
Ann. Onc., March 1, 2003; 14(3): 449 - 454.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
E. F. Smit, K. Mattson, J. von Pawel, C. Manegold, S. Clarke, and P. E. Postmus
ALIMTA(R) (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer: a phase II study
Ann. Onc., March 1, 2003; 14(3): 455 - 460.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. Freidlin, O. S. Breathnach, and B. E. Johnson
A Model to Select Regimens for Phase III Trials for Patients with Advanced-Stage Non-Small Cell Lung Cancer
Clin. Cancer Res., March 1, 2003; 9(3): 917 - 922.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
M. A. Socinski, D. E. Morris, G. A. Masters, and R. Lilenbaum
Chemotherapeutic Management of Stage IV Non-small Cell Lung Cancer
Chest, January 1, 2003; 123(1_suppl): 226S - 243S.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. J. Guarino, C. J. Schneider, S. S. Grubbs, D. D. Biggs, A. L. Himelstein, K. Hogaboom, and S. Tilak
A Dose-Escalation Study of Weekly Topotecan, Cisplatin, and Gemcitabine Front-Line Therapy in Patients with Inoperable Non-Small Cell Lung Cancer
Oncologist, December 1, 2002; 7(6): 509 - 515.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
O. Juan, A. Albert, F. Ordono, R. Casany, V. Caranana, J. M. Campos, and V. Alberola
Low-dose Weekly Paclitaxel as Second-line Treatment for Advanced Non-small Cell Lung Cancer: a Phase II Study
Jpn. J. Clin. Oncol., November 1, 2002; 32(11): 449 - 454.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
S. G. Spiro and J. C. Porter
Lung Cancer--Where Are We Today?: Current Advances in Staging and Nonsurgical Treatment
Am. J. Respir. Crit. Care Med., November 1, 2002; 166(9): 1166 - 1196.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G.V. Scagliotti, F. De Marinis, M. Rinaldi, L. Crino, C. Gridelli, S. Ricci, E. Matano, C. Boni, M. Marangolo, G. Failla, et al.
Phase III Randomized Trial Comparing Three Platinum-Based Doublets in Advanced Non-Small-Cell Lung Cancer
J. Clin. Oncol., November 1, 2002; 20(21): 4285 - 4291.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. E. Vokes, J. E. Herndon II, J. Crawford, K. A. Leopold, M. C. Perry, A. A. Miller, and M. R. Green
Randomized Phase II Study of Cisplatin With Gemcitabine or Paclitaxel or Vinorelbine as Induction Chemotherapy Followed by Concomitant Chemoradiotherapy for Stage IIIB Non-Small-Cell Lung Cancer: Cancer and Leukemia Group B Study 9431
J. Clin. Oncol., October 15, 2002; 20(20): 4191 - 4198.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
R. Rosell, U. Gatzemeier, D. C. Betticher, U. Keppler, H. N. Macha, R. Pirker, P. Berthet, J. L. Breau, P. Lianes, M. Nicholson, et al.
Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial
Ann. Onc., October 1, 2002; 13(10): 1539 - 1549.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. A. Bunn Jr
Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Who, What, When, Why?
J. Clin. Oncol., September 15, 2002; 20(90001): 23s - 33.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. A. Bunn Jr
Treatment of Advanced Non-Small-Cell Lung Cancer With Two-Drug Combinations
J. Clin. Oncol., September 1, 2002; 20(17): 3565 - 3567.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. K. Rowinsky
Taxane Analogues: Distinguishing Royal Robes from the "Emperor's New Clothes"
Clin. Cancer Res., September 1, 2002; 8(9): 2759 - 2763.
[Full Text] [PDF]

Home page